Twenty years ago, Columbia scientists created a way to make neurons in a dish, a discovery that has led to clinical trials of an experimental drug that may slow the progression of ALS.
Using EEG to identify covert consciousness in unresponsive brain-injured patients could help predict which ones may recover, find researchers at Columbia and NewYork-Presbyterian.
Research from Scott Small's lab at Columbia University suggests a different approach to tackling the disease, and a new startup company is now trying to turn that approach into treatments.
A gene called FMNL2 may explain why people with hypertension, diabetes, heart disease, or obesity have a greater risk of developing Alzheimer's disease.